advertisement

Topcon

Abstract #10190 Published in IGR 6-1

One-year follow-up of selective laser trabeculoplasty in open-angle glaucoma

Cvenkel B
Ophthalmologica 2004; 218: 20-25


BACKGROUND: Selective laser trabeculoplasty (SLT) targets the pigmented trabecular meshwork (TM) cells without damage to the adjacent non-pigmented tissue. A study was conducted to evaluate the efficacy and safety of SLT in the treatment of uncontrolled open-angle glaucoma. METHODS: In a prospective non-randomized study, 44 eyes of 31 patients with uncontrolled open-angle glaucoma were treated with a frequency-doubled, Q-switched Nd:YAG laser. A total of approximately 50 spots were placed over 180 degrees of the TM at energy levels ranging from 0.7-0.9 mJ. Intraocular pressure (IOP) was measured at one, two, and 24 hours, one and two weeks and one, two, three, six, nine, and 12 months after treatment. RESULTS: The average pre-operative IOP was 25.6 (SD 2.6) mmHg (range, 22-34). The mean IOP reduction from baseline at 24 hours, and three, six and 12 months was 7.1 mmHg (SD 3.5) or 27.6%; 4.2 mmHg (SD 3.5) or 16.4%; 4.7 mmHg (SD 4.2) or 18.6%, and 4.4 mmHg (SD 3.8) or 17.1%, respectively. The percentage of eyes with an IOP reduction of 3 mmHg or more at three, six and 12 months was 66, 78 and 62%, respectively. A pressure spike of 8 mmHg or more was detected in four eyes (9.1%). Anterior chamber reaction was seen one hour after SLT and was mild to moderate in 16 (40.4%) and marked in three (6.8%) eyes. CONCLUSIONS: SLT has shown reasonable efficacy in lowering IOP over a one-year follow-up, but there was a tendency for IOP to increase with a longer follow-up. Long-term follow-up studies in large samples are needed to determine whether the IOP lowering effect is sustained over time, and to assess the efficacy of repeated SLT.

Dr. B. Cvenkel, Eye Clinic, University Medical Centre Ljubljana, Ljubljana, Slovenia. barbara.cvenkel@kclj.si


Classification:

12.4 Laser trabeculoplasty and other laser treatment of the angle (Part of: 12 Surgical treatment)



Issue 6-1

Change Issue


advertisement

Oculus